KIT Mutation Analysis in Mast Cell Neoplasms: Recommendations of the European Competence Network on Mastocytosis

Overview

Journal Leukemia

Specialties Hematology
Oncology

Date 2015 Feb 5

PMID 25650093

Citations 111

Authors

M Arock

K Sotlar

C Akin

S Broesby-Olsen

G Hoermann

L Escribano

T K Kristensen

H C Kluin-Nelemans

O Hermine

P Dubreuil

W R Sperr

K Hartmann

J Gotlib

N C P Cross

T Haferlach

A Garcia-Montero

A Orfao

J Schwaab

M Triggiani

H-P Horny

D D Metcalfe

A Reiter

P Valent

Affiliations

Soon will be listed here.

Abstract

Although acquired mutations in KIT are commonly detected in various categories of mastocytosis, the methodologies applied to detect and quantify the mutant type and allele burden in various cells and tissues are poorly defined. We here propose a consensus on methodologies used to detect KIT mutations in patients with mastocytosis at diagnosis and during follow-up with sufficient precision and sensitivity in daily practice. In addition, we provide recommendations for sampling and storage of diagnostic material as well as a robust diagnostic algorithm. Using highly sensitive assays, KIT D816V can be detected in peripheral blood leukocytes from most patients with systemic mastocytosis (SM) that is a major step forward in screening and SM diagnosis. In addition, the KIT D816V allele burden can be followed quantitatively during the natural course or during therapy. Our recommendations should greatly facilitate diagnostic and follow-up investigations in SM in daily practice as well as in clinical trials. In addition, the new tools and algorithms proposed should lead to a more effective screen, early diagnosis of SM and help to avoid unnecessary referrals.

Citing Articles

Cold-induced anaphylaxis: new insights into clinical and genetic characteristics.

Bizjak M, Korosec P, Kosnik M, Selb J, Bidovec-Stojkovic U, Svetina M Front Immunol. 2025; 16:1558284.

PMID: 40061949 PMC: 11885499. DOI: 10.3389/fimmu.2025.1558284.

Management of Bone Health in Adult Mastocytosis.

Degboe Y, Nezzar C, Alary P, Maeva M, Livideanu C, Laroche M Curr Osteoporos Rep. 2025; 23(1):10.

PMID: 39946039 PMC: 11825596. DOI: 10.1007/s11914-025-00901-w.

Prevalence and incidence of mastocytosis in adults: a Danish nationwide register study.

Jorgensen M, Ovlisen A, Jensen J, El-Galaly T, Dalager M, Vestergaard H Eur J Epidemiol. 2025; 40(1):43-53.

PMID: 39751701 PMC: 11799073. DOI: 10.1007/s10654-024-01195-5.

Case Report: Multidisciplinary management of a patient with indolent systemic mastocytosis and refractory symptoms.

Hamilton M, Greene L, Madigan L, Wang S, Arana Yi C, Kuykendall A Front Allergy. 2024; 5:1401187.

PMID: 39493747 PMC: 11527781. DOI: 10.3389/falgy.2024.1401187.

Therapeutic advances of targeting receptor tyrosine kinases in cancer.

Tomuleasa C, Tigu A, Munteanu R, Moldovan C, Kegyes D, Onaciu A Signal Transduct Target Ther. 2024; 9(1):201.

PMID: 39138146 PMC: 11323831. DOI: 10.1038/s41392-024-01899-w.

References

Valent P, Akin C, Arock M, Brockow K, Butterfield J, Carter M . Definitions, criteria and global classification of mast cell disorders with special reference to mast cell activation syndromes: a consensus proposal. Int Arch Allergy Immunol. 2011; 157(3):215-25. PMC: 3224511. DOI: 10.1159/000328760. View

Wasag B, Niedoszytko M, Piskorz A, Lange M, Renke J, Jassem E . Novel, activating KIT-N822I mutation in familial cutaneous mastocytosis. Exp Hematol. 2011; 39(8):859-65.e2. DOI: 10.1016/j.exphem.2011.05.009. View

Miettinen M, Lasota J . KIT (CD117): a review on expression in normal and neoplastic tissues, and mutations and their clinicopathologic correlation. Appl Immunohistochem Mol Morphol. 2005; 13(3):205-20. DOI: 10.1097/01.pai.0000173054.83414.22. View

Mital A, Piskorz A, Lewandowski K, Wasag B, Limon J, Hellmann A . A case of mast cell leukaemia with exon 9 KIT mutation and good response to imatinib. Eur J Haematol. 2011; 86(6):531-5. DOI: 10.1111/j.1600-0609.2011.01598.x. View

Briley L, Phillips C . Cutaneous mastocytosis: a review focusing on the pediatric population. Clin Pediatr (Phila). 2008; 47(8):757-61. DOI: 10.1177/0009922808318344. View

Valent P, Arock M, Bonadonna P, Brockow K, Broesby-Olsen S, Escribano L . European Competence Network on Mastocytosis (ECNM): 10-year jubilee, update, and future perspectives. Wien Klin Wochenschr. 2012; 124(23-24):807-14. DOI: 10.1007/s00508-012-0293-z. View

Hauswirth A, Simonitsch-Klupp I, Uffmann M, Koller E, Sperr W, Lechner K . Response to therapy with interferon alpha-2b and prednisolone in aggressive systemic mastocytosis: report of five cases and review of the literature. Leuk Res. 2003; 28(3):249-57. DOI: 10.1016/s0145-2126(03)00259-5. View

Joris M, Georgin-Lavialle S, Chandesris M, Lhermitte L, Claisse J, Canioni D . Mast Cell Leukaemia: c-KIT Mutations Are Not Always Positive. Case Rep Hematol. 2012; 2012:517546. PMC: 3444844. DOI: 10.1155/2012/517546. View

Travis W, Li C . Pathology of the lymph node and spleen in systemic mast cell disease. Mod Pathol. 1988; 1(1):4-14. View

10.

Fritsche-Polanz R, Jordan J, Feix A, Sperr W, Sunder-Plassmann G, Valent P . Mutation analysis of C-KIT in patients with myelodysplastic syndromes without mastocytosis and cases of systemic mastocytosis. Br J Haematol. 2001; 113(2):357-64. DOI: 10.1046/j.1365-2141.2001.02783.x. View

11.

Jensen R . Gastrointestinal abnormalities and involvement in systemic mastocytosis. Hematol Oncol Clin North Am. 2000; 14(3):579-623. DOI: 10.1016/s0889-8588(05)70298-7. View

12.

Horny H, Ruck M, Kaiserling E . Spleen findings in generalized mastocytosis. A clinicopathologic study. Cancer. 1992; 70(2):459-68. DOI: 10.1002/1097-0142(19920715)70:2<459::aid-cncr2820700214>3.0.co;2-4. View

13.

Bibi S, Langenfeld F, Jeanningros S, Brenet F, Soucie E, Hermine O . Molecular defects in mastocytosis: KIT and beyond KIT. Immunol Allergy Clin North Am. 2014; 34(2):239-62. DOI: 10.1016/j.iac.2014.01.009. View

14.

Valent P, Horny H, Escribano L, Longley B, Li C, Schwartz L . Diagnostic criteria and classification of mastocytosis: a consensus proposal. Leuk Res. 2001; 25(7):603-25. DOI: 10.1016/s0145-2126(01)00038-8. View

15.

Foster R, Griffith R, Ferrao P, Ashman L . Molecular basis of the constitutive activity and STI571 resistance of Asp816Val mutant KIT receptor tyrosine kinase. J Mol Graph Model. 2004; 23(2):139-52. DOI: 10.1016/j.jmgm.2004.04.003. View

16.

Soucie E, Brenet F, Dubreuil P . Molecular basis of mast cell disease. Mol Immunol. 2014; 63(1):55-60. DOI: 10.1016/j.molimm.2014.03.013. View

17.

Erben P, Schwaab J, Metzgeroth G, Horny H, Jawhar M, Sotlar K . The KIT D816V expressed allele burden for diagnosis and disease monitoring of systemic mastocytosis. Ann Hematol. 2013; 93(1):81-8. DOI: 10.1007/s00277-013-1964-1. View

18.

Wohrl S, Moritz K, Bracher A, Fischer G, Stingl G, Loewe R . A c-kit mutation in exon 18 in familial mastocytosis. J Invest Dermatol. 2012; 133(3):839-841. DOI: 10.1038/jid.2012.394. View

19.

Vano-Galvan S, Alvarez-Twose I, de Las Heras E, Morgado J, Matito A, Sanchez-Munoz L . Dermoscopic features of skin lesions in patients with mastocytosis. Arch Dermatol. 2011; 147(8):932-40. DOI: 10.1001/archdermatol.2011.190. View

20.

Chabot B, Stephenson D, Chapman V, Besmer P, Bernstein A . The proto-oncogene c-kit encoding a transmembrane tyrosine kinase receptor maps to the mouse W locus. Nature. 1988; 335(6185):88-9. DOI: 10.1038/335088a0. View